The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called benfotiamine as a possible treatment for Alzheimer’s disease (AD). Benfotiamine is a lab-made version of vitamin B1 (thiamine). The study aims to determine whether the drug slows down the progression of the symptoms of early Alzheimer’s disease. Participants will be randomly assigned to receive either the study drug or placebo (inactive substance).
Not Available
What is the full name of this clinical trial?
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer?s Disease